Cargando…
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
INTRODUCTION: HIV/HCV coinfection is a risk factor for hepatic injury in patients receiving HAART and previous studies support a favourable effect of antiretroviral regimens including maraviroc (MVC) on the course of coinfection compared with other antiretroviral drugs. There are few observations ab...
Autores principales: | Gagliardini, Roberta, Rossetti, Barbara, Bianco, Claudia, Rusconi, Stefano, Colafigli, Manuela, Prinapori, Roberta, Francisci, Daniela, Fantauzzi, Alessandra, Orofino, Giancarlo, Vignale, Francesca, Di Giambenedetto, Simona, De Luca, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International AIDS Society
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225435/ https://www.ncbi.nlm.nih.gov/pubmed/25397562 http://dx.doi.org/10.7448/IAS.17.4.19818 |
Ejemplares similares
-
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study
por: Bianco, Claudia, et al.
Publicado: (2014) -
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study
por: Rossetti, Barbara, et al.
Publicado: (2019) -
Lung Transplantation for Post COVID19 End Stage Lung Failure: A Case Series from 3 Latin American Countries
por: Undurraga, P.F., et al.
Publicado: (2022) -
Dosage de la vitamine D chez les patients hospitalisés pour pneumopathie à Covid-19 dans le service de pneumologie du CH Chauny, France
por: Kone, A., et al.
Publicado: (2022) -
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial
por: Rossetti, Barbara, et al.
Publicado: (2017)